Primary biliary cirrhosis is a chronic disease that causes the bile ducts in the liver to become inflamed and damaged and, ultimately, disappear. Bile is a liquid produced in the liver that travels through the bile ducts to the gallbladder and then the small intestine, where it helps digest fats and fat-soluble vitamins A, D, E, and K. When the bile ducts become damaged from chronic inflammation, bile builds up in the liver, injuring liver tissue.
Researchers have newly identified three genetic regions associated with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, increasing the number of known regions associated with the disorder to 25.
Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.
Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on an application for orphan medicinal product status for the company's lead hepatology candidate, A4250.
An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol.
Nonalcoholic steatohepatitis (NASH) occurs when fat builds up in the liver. This accumulation of fat damages the liver and leads to cirrhosis. NASH is rapidly increasing in the U.S. mainly related to the epidemics of obesity and diabetes.
Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.
Apollo centre for liver disease and transplantation has completed 100 liver transplantations in less than 4 years with over 90% success rate, creating a milestone in the history of medicine.
Results from an international study presented today at the International Liver Congress have shown Obeticholic Acid (OCA) is a safe and effective treatment in patients suffering from Primary Biliary Cirrhosis (PBC) as demonstrated by substantial decreases in the levels of alkaline phosphatase (AP) enzyme in the blood, a key marker for PBC.
Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.
Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.
Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.
Vitamin D deficiency is a well reported complication in chronic cholestatic liver disease such as primary biliary cirrhosis. While the prevalence and treatment of this deficiency has been addressed in many articles over the last decades, little is known of the vitamin D status in alcoholic liver cirrhosis.
Researchers have provided new clues into the genetics underlying a chronic form of liver disease, called primary biliary cirrhosis, which can lead to transplant surgery for patients.
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).
A study conducted by researchers at Johann Wolfgang Goethe University in Frankfurt, Germany found that high doses of ursodeoxycholic acid, suggested by some studies to have a beneficial effect on nonalcoholic steatohepatitis, does not improve overall histology in these patients. Full findings of this study are published in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.
St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.
Results of a study presented today at the at the International Liver CongressTM 2010 reveals the effects of a new drug for the treatment of primary biliary cirrhosis, and shows further evaluation is necessary.
Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune liver diseases. However, further studies are necessary in order to validate the diagnostic utility of IgM and IgG immunohistochemistry in this specific scenario.
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.
Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.